Category: Sciences

The MarketWatch news department was not involved in the creation of this content.

Feb. 09, 2023 (The Expresswire) – "Analysis of the impact of COVID-19 on the industry will be added to the final report."

Global "Life Sciences Market" 2023-2028 provides comprehensive and high-quality information on innovative business growth strategies, macro and micro economic factors, trend assessments and key players' economic statements. This report (107 pages) provides a major roadmap of recent growth opportunities from major key players, as well as future business perspectives and developments. This report provides detailed information about the company as well as business plans and new investment ideas in all regions such as North America, Asia and Europe. In addition, Life Sciences market report provides share estimates as well as CAGR status, revenue growth data, industry size and segment analysis.

মার্কেটওয়াচ নিউজ এই তৈরির সাথে সাথে জড়িত নান

2022

Bangor – Bay University is pleased to offer a number of Health Science degrees. The course starts on February 27.

Health science is a relatively new academic discipline, according to an article in US News. Although many universities do not have well-established health science programs, there are many reasons to consider pursuing a health science degree.

1. Start working quickly in various medical professions

Health sciences focus on health issues rather than basic sciences (such as biology or chemistry). This reassignment broadens students' understanding of many areas of health care.

Left to right: Gary Tischler and Richard Coles of the Vanburton Group together at 3 West 29th Street (Getty, Vanburton Group, Google Maps)

One of New York's most anticipated office projects certainly seems to be changing.

The VanBurton Group is considering developing its vacant lot next to Marble Collegiate Church at West 29th Street and Fifth Avenue as a life sciences project rather than an office tower, according to a person familiar with the matter. When finished, it will be one of the largest projects in the city.

The latest attack on the site comes more than seven years after the community formed a joint venture with Jill Feldman's firm HFZ Capital, which originally designed the 64-story residential tower at 3 West 29th Street next to the historic church at 272 Fifth Ave.

By 2019, HFZ had moved into a 34-story office tower called 29 and 5 and designed by Bjarke Ingels. Soon after, the Zona Franca's multibillion-dollar real estate portfolio began to collapse due to a wave of loans and foreclosures.

Van Burton, the intermediate lender on the project, relinquished its interest in the joint venture and acquired the site in 2021. It appears to be primarily promoting plans for an office tower. It hired the architectural firm Kohn Pedersen Fox, designers of the ultra-tall SL Green One Vanderbilt, and construction was scheduled to begin last year.

But VanBurton hasn't submitted a plan since then and the job remains open. The source said it could build a life sciences project on the land immediately and the site could be used by local hospitals.

A potential shift toward life sciences looms as the Manhattan office market suffers from low demand. Some office owners want to convert their properties into living space, but the process can be expensive and not suitable for all buildings.

Life science is one of the most popular sectors of real estate. About 20 million square feet of space is expected to be offered to life sciences tenants this year, according to a report by Cushman & Wakefield.

New York lags other cities like Boston and San Francisco in life sciences construction, but Taconic Partners is renovating a vacant 400,000-square-foot building into a life sciences research facility at 125 West End Avenue.

The Nomad site was an innovative development in the Hamria Free Zone. The Marble Collegiate Church, founded in 1628, is one of the oldest Protestant denominations in the country. Best known for Pastor Norman Vincent Peale, author of The Power of Positive Thinking, the church once counted Donald Trump among its members.

Investor filings show the projected cost of the planned HFZ project is $1.3 billion as of 2019, and the church plans to use development funds to restore the existing 1851 building and build a public facility at the base of the new tower. Now you probably won't have any involvement in the project.

Van Burton declined to comment.

Today, early detection of cancer is much more common than it was ten years ago. Exact Sciences ( NASDAQ:EXAS ) can't claim all the credit, but the non-invasive cancer tests it sells play an important role. About 4 million people will be screened for cancer by the company in 2021.

Despite its product's large audience, Exact Science's shares have fallen nearly 40% in the past year and are still below their peak of 56% in early 2021. Risky for most investors. Here's what you need to know.

Reasons to buy stocks in sound science

Exact Sciences introduces ColoGuard, a non-invasive colon cancer screening. It continues to channel Cologuard's revenue into innovative new cancer detection methods, including multiple cancer early detection (MCED) tests for the general public. Success in the highly sought-after MCED arena could push this stock higher, and Exact Sciences continues to move forward.

Last September, a blood test that tested 1,132 samples for four different cancer markers found that 61% of the samples had cancer. It is not very sensitive, but the lack of false positives is very reassuring. Exact Sciences also reported a specificity rate of 98.2%, meaning that almost all reported samples actually came from people with known cancer.

Exact Science's flagship test, ColorGuard, will soon receive an update called ColorGuard 2.0. In early 2022, the company tested samples from the Deep-Sea trial that led to the initial approval of ColoGuard using ColoGuard 2.0, and the results were very encouraging.

Investors worry about potential competition from Guardian Health 's ( NASDAQ:GH ) blood-based Shield test Fortunately for the exact science, last December's Shield test produced disappointing results that strongly suggest Cologuard 2.0 wins.

Reasons to be cautious

Sound science knows how to sell millions of cancer tests, but monetizing them is another story. The company continues to invest heavily in new initiatives such as the MCED program, which has not been successful. As a result, the company has been facing huge losses in recent quarters.

© YCharts EXAS Net Income (Quarterly)

Young companies in the high growth phase often lose money trying to gain market share. Unfortunately, the exact science of cancer screening is stagnant. In the third quarter of 2022, the company's flagship cancer screening screened 960,000 people, just 10,000 more than the previous year.

Why now?

Exact Sciences is far from its previous peak, but there is still plenty of optimism at current prices. The stock is currently selling at 6 times. This is a relatively low figure for Exact Science, but surprisingly high compared to its larger rivals Quest Diagnostics and LabCorp , which trade at 1.7x and 1.6x sales, respectively.

Across different tests, Exact Sciences should maintain higher rates than LabCorp or Quest. Unfortunately, staying ahead of the competition requires such large investments that the company believes it won't be able to report adjusted earnings until the third quarter of 2023. In accordance with generally accepted accounting principles.

Brand loyalty is low in the diagnostic industry. Doctors usually choose the best test based on clinical trial data. Cologuard has done well, but it's always a matter of time before a good mousetrap is made. So I would not buy Exact Science or any other diagnostics company that is not already in steady growth in profits.

Sponsor:

10 stocks we love more than exact science

When our team of award-winning analysts have stock advice, it's worth listening. After all, the Motley Stock Advisor newsletter has doubled the market they've been operating for over a decade*.

They've just revealed what they think are the ten best stocks investors can buy right now…and exact science isn't one of them. That's right, they think these 10 stocks are a good buy.

Check out 10 promotions

* Stock advisor returns on January 9, 2023

Corey Renauer has no positions in any of the listed stocks. The Motley Fool has a position and recommends Guardian Health. The Motley Fool recommends Exact Sciences and Quest Diagnostics. Motley Fool has a disclosure policy.

"The Bloody Fall of the 90s and 80s Cycles, Harry Dent, Crypto Interview

As 2023 begins, following a trend professionals in The Woodlands, Texas and the greater Houston area are just beginning to see, some are seeing a number of announcements from companies relocating or expanding their presence in the region, including some from California.

According to the Woodlands Area Economic Development Partnership, as of 2019, The Woodlands saw changes across employment sectors as energy companies reduced their presence or moved out of the area and healthcare employment increased as businesses expanded.

Economic experts in the region note that these factors, as well as factors such as a favorable business environment, have increased the attractiveness of the region for many foreign companies, especially in the life sciences sector.

A 2022 study by Stanford University's Hoover Institution found that at least 132 businesses moved from California to Texas in 2018-21.

That's more than four times the second-highest number of actions in California, Tennessee, which had 31 corporate actions.

Gil Staley, chairman of The Woodlands Area EDP, said interest from science and technology companies is creating new businesses in the area that George Mitchell and The Woodlands founders originally envisioned for such companies.

"We see this as a rebirth of the research forest [corridor]," Staley said.

In 2022, two California life sciences companies announced they will relocate their headquarters or establish a presence in The Woodlands.

Cellipont Bioservices, which develops and manufactures cell therapies for other companies, opened a 76,000-square-foot manufacturing facility in November at 9501 Lakeside Blvd.

Work also began in late December on a suite for Nurix Therapeutics at 8800 Technology Forest Place as part of a larger life science complex.

Joel Marcus, CEO and founder of Alexandria Real Estate Equities Inc., the California-based company developing the complex, said the campus will be about 318,000 square feet when complete.

The first phase will be completed in the first quarter of 2023.

"There will be nothing like this in Houston, on a uniquely safe and accessible campus," Marcus said.

field of life sciences

In an area once home to energy companies like Anadarko, the energy sector's share of non-retail jobs among large employers has fallen from 27% to 8% since 2019. By the beginning of 2022, healthcare accounted for more than 30%. According to The Woodlands Area EDP.

This growth in health care is part of what makes the region attractive for life sciences, said Kathy Pryor, chief development officer and senior vice president of membership for the Greater Houston Partnership, the region's future events hub.Houston Dec. 12. 13.

"Increased interest in economic development in the region, particularly in Montgomery County, has recently created tremendous opportunities for innovation and growth in the industrial and technology sectors," Pryor said at the event.

California-based companies have taken note, and Deborah Wilde, president and CEO of Cellipont, said The Woodlands is a good fit for the company, both financially and logistically.

"We did a regional analysis … and found that economically the wooded area is a great location for workers," Wilde said. "When schools are good, staff stay longer. This is a beautiful and safe place."

Stella Vnuk, Cellipon's chief scientific officer, said the area is ideal for companies like Cellipon because of its proximity to the Texas Medical Center and Houston-area airports, as well as its growing scientific research and innovation community.

Texas is also a central location within the country and an important factor in the rapid transport of sensitive biological materials over long distances.

"A lot of innovation is coming from the Texas region. … It is very important for us to further develop and expand cell therapy in this very important region,” said Vnuk.

Wilde said the company has 70 employees in San Diego, and although some executives will relocate, most of the new hires will be local. Once fully completed, he plans to add a manufacturing component to the site, which will employ about 200 people, he said.

A larger complex is planned for the Technology Forest location, formerly occupied by Lexicon Pharmaceuticals and moving to Technology Forest Boulevard.

The former 260,000-square-foot campus will be transformed into a life sciences campus that will offer more than 300,000 square feet of office and laboratory space, as well as meeting rooms, a fitness center and courts, according to Sarah Kabakoff. . . Vice President of Strategic Communications, Alexandria.

“We chose The Woodlands to redesign and develop a unique, mission-critical, multi-tenant, co-working campus under the Alexandria brand that will bring to the Houston area market a highly convenient and secure workspace for the first time: a vibrant environment for life. sciences and other advanced technology companies, Marcus said in an email.

The first company to announce plans to lease space in the area is San Francisco-based Nurix Therapeutics. According to The Woodlands Area EDP, the company held a groundbreaking ceremony for the project on December 13. According to Alexandria, the company is working on protein modulation for cancer treatment. The company will operate its own research and development facility in the country.

national interests

Jim Carman, president of The Howard Hughes Corp.'s Houston region, said 33 businesses plan to relocate or expand within their leases in The Woodlands by 2020, representing more than 500,000 square feet of office space and 2,000 new residents. works. after.

Howard Hughes leases space on the 31st and 32nd floors of The Woodlands Towers to The Waterway, formerly Anadarko Towers, which it purchased in late 2019.

The tower at 9950 Woodloch Forest Drive will house several new corporate headquarters or offices, including Obagi Cosmeceuticals, which is moving from California, and Centric Infrastructure Group, which is moving from The Woodlands. New York cryptocurrency firm NYDIG is also setting up office space there.

"Over the past few years, we've definitely seen a diversification of our client organizations," Carman said. "One of the most interesting ones is really some of the companies in the renewable business space."

These companies include Lancium Technologies, which is moving from Texas to an entire floor of The Woodlands Towers in 2022. The company works with renewable energy infrastructure and technology.

Other tech companies moving from The Woodlands include SmartDraw Software, which is moving from California to Hughes Landing in 2022, and chemicals and pharmaceuticals company SI Group, which is moving from New York in the fall, according to Howard Hughes Of.

Although many companies are moving to remote work, the need for office space is still great, Carman said. Office leasing in The Woodlands was more resilient than in the greater Houston area during the third quarter, with The Woodlands having a 23.3% vacancy rate of 16.6%, according to real estate brokerage Colliers.

Businesses moving to The Woodlands are also drawn to the community's proximity to jobs and services, he said.

"These companies' real estate needs haven't changed significantly. They need the same square footage," Karman said. “The difference is more focus on comfort. When our employees come to the office, we give them more reasons to be there than just a paycheck and a desk.

Prepare future employees

Companies moving to The Woodlands will primarily hire locally, Staley said.

"They want to see a very well-trained workforce to hire," Staley said.

According to the Census Bureau's 2021 American Community Survey Five-Year Estimates, 64.3 percent of Woodlands residents age 25 and older have a bachelor's degree or higher, compared to the national average of 33.7 percent.

According to him, the presence of companies in new fields, such as life sciences, can also help advance educational programs.

Staley said EDP plans to begin discussions with the Lone Star College System in early 2023 to discuss life science programs.

LSCS deputy director Linda Head said plans could include courses for medical labs and production technicians, as well as cleanroom courses and continuing education for employees.

"We're working very quickly to design the right programs and labs and change what we need to be ready in about six months," Head said.

US Navy SEAL videos leaked

Urovant Sciences announces its partnership with Holly Robinson Peet, actress and OAB patient, as part of the Time To Go™ campaign, an OAB awareness program. The Time to Go campaign aims to highlight the impact the disease can have on patients and present options for managing OAB symptoms so that people living with OAB feel more secure. comfortable asking for help finding a healthcare professional.

“We are thrilled to partner with Holly Robinson Peete to help raise awareness about overactive bladder and reduce the stigma surrounding the disease,” said James Robinson, CEO of Urovant Sciences. "We believe this collaboration will lead to greater awareness of symptoms and treatment options that may be helpful."

Overactive bladder causes sudden urges that are hard to control and can lead to leaking and frequent urination, usually eight or more times a day. Because millions of Americans experience bladder symptoms, the prevalence increases with age. Overactive bladder can negatively affect daily activities, such as B. changing travel plans, doing little or no exercise, and making daily activities difficult. Pete has first-hand experience with OAB, having been diagnosed last year, and has since dedicated his time and resources to managing the symptoms for himself and others.

Peete's overactive bladder diagnosis wasn't as obvious as he thought; she remembered accidentally having to go to the bathroom. At first, she thought the symptoms were a normal part of aging, especially since menopause was difficult for Pete at the time. She explained that offline address book symptoms are not necessarily part of aging and that we should discuss an appropriate plan for my symptoms,” she told ESSENCE.

Subsequently, her doctor recommended GEMTESA among her treatment options, a prescription drug to treat bladder problems in adults with episodic symptoms, urgency, and frequency of urination; Thinking about it, he wished he'd told the doctor sooner. "I had OAB symptoms for years before I talked to my doctor about treatment options and wish I had had some sooner," Pete said. "I realized that I used to go to the bathroom a lot and I suddenly had the urge to go, like now. With my overactive bladder symptoms, there was a lot of stress and anxiety before traveling for work or pleasure. I have noticed a positive effect on my offline address book symptoms with GEMTESA. By reducing my symptoms, I spend more time planning activities and less time plan the nearest toilets.

Pete isn't the only one who noticed his symptoms afterwards. According to a study published in the Journal of Urology, many people with symptoms of an overactive bladder are hesitant to see a doctor. This may be because they're too shy to talk about their symptoms or mistakenly believe it's part of normal aging.

Prior to taking GEMTESA, Pete had difficulty going out in public and was unable to train in the gym. He began to feel how his bladder was affecting his quality of life. "For the first time, I noticed that OAB was interrupting my work. Looking back, I have adjusted many aspects of my life. The first thing I asked upon entering the restaurant was: " Where's the toilet?" I even made special requests for the closets so I could go to the bathroom quickly and easily," says Pete.

Since GEMTESA is part of her wellness regimen, she has now improved her OAB symptoms and goes to the bathroom less often without worrying about being out of the house and the bathroom. He also thanks his group of trusted friends for his recovery. "My friends give me a lot of strength, so start with an honest and open conversation with them. They are the people I share my innermost thoughts and aspirations with, and maybe by sharing my story I can help one of them open up,” He says.

With this new campaign, Pete wants to encourage the black community to share their truth and get help. “In our community, we often feel uncomfortable talking about intimate matters, and when it comes to our bodies and our health, we shouldn't be. By being open about issues like an overactive bladder, we can help break down this often pervasive stigma. and get the attention we need,” he says.

Visit TimeToGo.com to learn more about OAB and GEMTESA®

Exact Sciences (EXAS) closed the last trading day at $67.92, down 0.67% from the previous trading session. The move was smaller than the S&P 500's 1.56% decline for the day. Elsewhere, the Dow lost 1.81% while the Tech-Nasdaq lost 4.66%.

The molecular diagnostics company's shares were up 33.84% month-on-month today. Meanwhile, the medical sector was up 0.86% and the S&P 500 was up 3.82%.

Investors are looking to Exact Science for strength as it heads into its next earnings report. In this report, analysts expect Exact Sciences to report earnings of -$0.92 per share. It will grow by 28.13% per year. Meanwhile, our latest agreed estimate was revenue of $527.13 million, up 11.25% from the year-ago quarter.

Investors should also pay attention to recent changes in analyst forecasts for the exact sciences. The recent correction reflects the recent short term trading trend. Thus, the positive revision of the forecast reflects analysts' optimism about the company's business and profitability.

Based on our research, we believe this rework is directly related to the team's inventory movement. We took advantage of this phenomenon and created Zacks Rank. Our system takes these changing assumptions into account and provides a clear and efficient scoring model.

Ranging from #1 (strong buy) to #5 (strong sell), the Zacks Rating system has an impressive track record, backed by external audits, with the #1 stock up +25% since 1988 Earning a CAGR. Last month, Zacks. The consensus EPS estimate is up 4.54%. Exact Science is currently ranked #2 Zack (Buy).

Drug. The biomedical and genetic industries are part of the medical sector. The industry currently has a Zacks 70 industry rating, placing it in the top 28% of 250+ industries.

Zacks Industry Ratings evaluates the strength of our industry group by measuring the average Zacks rating of each stock in the group. Our research shows that the top 50% of the industry outperforms the bottom by a factor of 2 to 1.

For more information on all of these metrics and more, visit Zacks.com.

To read this article on Zacks.com, click here.

Fed Day | See Bloomberg 14/12/2022

text size

Cancer testing company Exact Sciences did not expect to report the results until the September quarter. But test seller Cologuard said sales growth in the December quarter helped boost profits earlier than expected.

Sunday in Madison, Wisconsin. Revenue rose 28% to more than $550 million in the last quarter of 2022, according to preliminary data released by the company. Sales of colorectal cancer screening products, such as the Cologuard stool test, have increased by more than 40%.

MedCity Invest Precision medicine. The perfect move. Presentations of startups in the field of life sciences: